Market Exclusive

Zoetis (NYSE:ZTS) reported earnings of $0.77 per share beating Walls Streets expectations.

Zoetis (NYSE:ZTS) reported Q2 2018 earnings this Morning, coming in at $0.77 per share, beating Wall Street’s estimates of $0.70 per Share. Revenue for the quarter came in at $1.42 billion beating analyst estimates of $1.38 billion Recent Insider Trading for Zoetis (NYSE:ZTS)

Dividend History for Zoetis (NYSE:ZTS)

About Company Zoetis Inc. discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. In addition, the company offers other product categories, including nutritionals and agribusiness services, as well as products and services in complementary areas, such as biodevices, diagnostics, and genetics. It markets its products to veterinarians, livestock producers, and people who raise and care for farm and companion animals through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.Recent Analyst Rating for Zoetis (NYSE:ZTS)